CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® technology platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against these targets, today announced that Brian Pereira, MD, President and Chief Executive Officer, will present a company overview at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017, at 10:40 a.m. ET in New York City.
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against disease targets that are not adequately addressed with conventional approaches. These targets include viruses and bacteria – which have a high degree of diversity among strains with frequent mutations – and proteins within the body. Visterra’s lead product candidate, VIS410, is a monoclonal antibody in development for the treatment of hospitalized patients with influenza A, regardless of the viral strain. The company’s second product candidate, VIS513, is a monoclonal antibody in development for the treatment of Dengue, and its third product candidate, VIS649, is a monoclonal antibody in development for the treatment of IgA Nephropathy. In addition, the company is developing an antibody-drug conjugate candidate, VIS705, as a single-dose curative therapy, engineered to kill all strains of the deadly Pseudomonas aeruginosa bacteria, including the potential for multi-drug resistant strains. For more information, please visit www.visterrainc.com.